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The skin barrier, located in the stratum corneum, is in-
fluenced mainly by the lipid and protein composition of 
this layer. In eczematous diseases impairment of the skin 
barrier is thought to be of prime importance. Topical 
anti-inflammatory drugs and emollients are the most wi-
dely used eczema treatments. The aim of this study was 
to examine the effects of topically applied corticosteroid, 
tacrolimus and emollient on stratum corneum lipids and 
barrier parameters. Nineteen healthy volunteers partici-
pated in the study. Both forearms of the subjects were di-
vided into four areas, which were treated twice daily for 
one week with betamethasone, tacrolimus, emollient, or 
left untreated, respectively. After one week each area was 
challenged with a 24 h sodium lauryl sulphate patch test. 
The lipids were collected using the cyanoacrylate method 
and evaluated by high performance thin layer chroma-
tography. For evaluation of the skin barrier, transepi-
dermal water loss, erythema and electrical capacitance 
were measured. The ceramide/cholesterol ratio was in-
creased in betamethasone- (p = 0.008) and tacrolimus-
treated (p = 0.025) skin compared with emollient-treated 
skin. No differences in ceramide subgroups were found 
between treatment regimes. Pretreatment with betame-
thasone (p = 0.01) or with tacrolimus (p = 0.001) causes a 
decreased inflammatory response to sodium lauryl sul-
phate compared with emollient. In conclusion, treatment 
with betamethasone and tacrolimus has a positive effect 
on the ceramide/cholesterol ratio and susceptibility to ir-
ritant reaction compared with an emollient. Key words: 
ceramides; corticosteroid; emollient; lipids; skin barrier; 
tacrolimus.
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Skin barrier impairment is thought to be of prime im-
portance in eczematous diseases and has been studied 
extensively in atopic dermatitis (AD) and irritant eczema 
(1, 2). The barrier function of the skin is located in the 
stratum corneum (SC) and is influenced mainly by the 
lipid and protein composition of this layer (3, 4). The 
protein, filaggrin, has been shown to play a major role, 
while for lipids, the ceramide profile in particular has 
been reported to be affected. In patients with AD, a de-
creased amount of ceramide 1 and 3 is characteristically 
found (5–7). Recent data, however, suggest that ceramide 
profiles are not correlated with filaggrin mutations, sug-
gesting that the two mechanisms appear to be mutually 
independent (8). 
Topical application of anti-inflammatory drugs and 
emollients is frequently used for treatment of eczema. 
Traditionally, topical corticosteroids have been used, 
but in recent years non-steroidal alternatives, such as 
tacrolimus and pimecrolimus, have been used increa-
singly, in particular in the treatment of AD. The effect 
of topical corticosteroids on inflammatory dermatoses 
has been well documented (9), as has the effect of topi-
cal tacrolimus on AD and, to a lesser degree, on other 
eczematous diseases (10). Whereas the effects of these 
drugs on inflammation are well established, their effect 
on barrier integrity is less well described. Irrespective 
of the anti-inflammatory effect of these drugs, any ad-
ded iatrogenic impairment of barrier function would 
be undesirable from the point of view of the current 
understanding of the disease pathogenesis of AD and 
irritant eczema. However, it has been suggested that the 
use of topical corticosteroids potentially damages the 
skin barrier further, and hence is counterproductive in 
the treatment of skin diseases where barrier impairment 
is a core element of the pathogenesis (11, 12). The use 
of corticosteroids may lead to a decrease in the number 
of lamellar bodies, and thereby, a decrease in SC lipids, 
which is of particular concern when treating AD (12). A 
recent study has examined consequences of the use of 
betamethasone treatment on people with AD, and found 
that it led to inconsistent extracellular lipid bilayers (11). 
In contrast, it has been speculated that tacrolimus could 
normalize the abnormalities in the lipid composition of 
AD (13). The effect of tacrolimus on the SC lipids in 
AD patients has been studied in an uncontrolled study, 
and no effect found (13). 
The positive clinical effect of emollients on eczema 
is well known, and their use is generally recommended 
as adjuvant therapy of both AD and irritant eczema. In 
spite of their widespread use, the effect of emollients 
on the lipid composition of human skin, in both healthy 
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and diseased skin, is comparatively poorly described 
(14–19) and further investigation is required.
The aim of this study was to identify the effect of 
topical betamethasone and tacrolimus on skin barrier 
function, structurally with respect to SC lipids, and 
functionally through the susceptibility to challenge 
with an irritant.
MATErIALS AND METHODS
Nineteen healthy participants with no former history of any 
major skin diseases were included in the study (6 men and 13 
women, median age 25 years, age range 18–51 years). Parti-
cipants were enrolled after responding to posters at the local 
educational centres and the library. The study was approved by 
both the local ethics committee (SJ-7-17583-3) and the Eudra 
CT (2008-000819-15) for the use of drugs.
Four areas (4 × 7 cm2) on the volar forearms on each partici-
pant, two on each forearm, were randomized for treatment twice 
daily with betamethasone-17-valerate (Betnovat®; glaxoSmith-
Kline Pharma), tacrolimus (Protopic®; Astellas) or emollient 
(Olefin®, per 100 g: white Petrolatum 15 g, Parafine oil 6 g, 
Cetomacrol 1000 1, 8 g, Cetostearyl alcohol 7.2 g, Chlorcresol 
0.1%, glostrup apotek, glostrup, Denmark) respectively, and 
one area was left as untreated control. The distances between 
the treated areas were approximately 4 cm. The participants 
were instructed in how much ointment (approximately 1.5 g/
day) to apply on the skin (20), and treatment was performed 
twice daily for 7 consecutive days. In the morning the topical 
treatments were applied under supervision of a physician, and 
in the evening, by the participants themselves, after being 
reminded by a text message (SMS).
The topical treatment was applied for the last time in the eve-
ning of day 7. On day 8 all participants were examined with non-
invasive measurements (see below). On each of the four areas a 
1% sodium lauryl sulfate (SLS) (Sigma-Aldrich > 99.0% purity, 
Sigma Aldrich, St Louis, USA) patch was placed, using Large 
Finn-Cambers® (12 mm) with filter discs (60 µl) (21), and adjacent 
to this a cyanoacrylate sample was taken for lipid analysis (22). 
SLS patches were removed after 24 h (day 9), and on day 10 the 
non-invasive measurements trans-epidermal water loss (TEWL) 
and erythema were repeated. Cyanoacrylate samples were obtained 
from 16 of the 19 patients, due to practical difficulties.
For non-invasive measurements, TEWL was measured using a 
Dermalab® (Cortex Technology, Hadsund, Denmark), following 
recommended guidelines (23), two measurements were perfor-
med and the mean value used for further calculations. 
Erythema was assessed by a croma meter (Minolta croma Me-
ter CR-300, Minolta Camera Co., Osaka, Japan), which expres-
ses colour in the L*a*b system, where erythema is expressed as 
a*, in accordance with guidelines (24), two measurements were 
taken and the mean value used for further calculations.
Capacitance was measured using a corneometer (CM825PC, 
Courage + Khazaka, Köln, Germany), which expresses an 
arbitrary unit, representing the water content of the SC. Three 
measure ments were performed and mean values used for further 
calculations (25).
For the cyanoacrylate method, a method recently found best 
suited for the use on human skin (22), the chosen area was wiped 
with acetone to eliminate contamination from surface lipids. A drop 
of cyano-acrylate tissue-glue (LiquiBand®) was placed at one end 
of a glass-slide and held tight against the skin, until it dried, and was 
then removed. The samples were kept at –80ºC until lipid extrac-
tion and analysis by high performance thin layer chromatography 
(HPTLC). Lipids were extracted from the cyanoacrylate and sepa-
rated on silica-gel HPTLC plates. Development of the plates was 
carried out in chloroform:methanol:acidic acid (190:9:1(v:v:v)). 
The plates were stained with primuline and lipids were quantified 
based on fluorescence intensity (Desaga TLC Densitometer CD 
(Desaga gmbH, Wiesloch, germany), using standard curves made 
from ceramide 5 and cholesterol (Matrega, LLC, Pleasant Gap, PA, 
USA). For details, this method is described thoroughly elsewhere 
(22). This set-up describes relative differences in ceramide sub-
groups and ceramide/cholesterol ratio. 
Statistics
Friedman’s test was used as an omnibus test for more than two 
groups, including parameters from all four areas. If this test achie-
ved statistical significance, the Wilcoxon matched pairs test was 
applied for pair-wise comparison. p < 0.05 was chosen as the level 
of significance. Data were analysed using SPSS statistics 17.0.
rESULTS
Skin lipids in stratum corneum 
Ceramide/cholesterol ratio and ceramide profile from 
the four test areas after 7 days of topical treatment 
are given in Fig. 1. Statistical significant difference 
between the treatment regimes was found for the cera-
mide/cholesterol ratio. The highest median ratio was 
found for the area treated with betamethasone, and sta-
tistically significant higher than emollient (p = 0.008), 
but also tacrolimus had statistically significant higher 
ceramide/cholesterol ratio than emollient (p = 0.025). 
No statistically significant difference was found for 
the ceramide/cholesterol ratio between untreated con-
trol and the different treatment regimes. For ceramide 
1–9, no statistical significant differences were found 
between test areas, and no obvious tendencies between 
any of the treatment regimes. 
Functional evaluation of skin barrier function
TEWL, erythema and capacitance measurements after 
different treatment regimes are presented in Table I.
With respect to TEWL values from the four test 
areas after 7 days of topical treatment, a statistically 
significant difference between the different areas was 
found, with the lowest values in the betamethasone-
treated area, followed by the tacrolimus-treated area. 
However, no pair-wise statistically significant difference 
was found between any of the treated areas or for the 
untreated area.
With respect to TEWL values after the SLS-irritation 
performed after the different treatment regimes, no sta-
tistically significant difference was found between the 
different treated areas. The betamethasone-treated area, 
however, still had the lowest TEWL values (Table I). 
For erythema measurements from the four test areas 
after 7 days of topical treatment, we found statistically 
significant differences for a*, with betamethasone sho-
wing statistically lower levels of erythema than both 
tacrolimus and untreated control (Table I). Decreased 
Acta Derm Venereol 91
292 J. M. Jungersted et al.
erythema after SLS-irritation was found in betame-
thasone- and tacrolimus-treated skin compared with 
emollient-treated skin. Increased erythema after SLS-
irritation was found in emollient-treated skin compared 
with untreated control.
For capacitance evaluated 24 h after the last appli-
cation of the topical treatment regimes, no statistical 
significance was found (Table I). 
DISCUSSION
Topical treatment regimes with corticosteroids and 
tacrolimus are used widely for eczematous diseases, 
and improved understanding on their influence on the 
skin barrier function is therefore needed. 
It is well known that the skin barrier is impaired in 
eczematous diseases, and that the barrier function is in-
Cer 1     Cer 2+9           Cer 3    Cer 4        Cer 5+8          Cer 6      Cer 7                       Cer/Chol
Betamethasone
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Tacrolimus
Untreated control
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Ceramide profile
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Fig. 1. Percentages of median ceramide values from 
four different treatment regimes. Note that ceramide/
cholesterol is not in percentages but illustrates a ratio. 
Error bars illustrate 1st and 3rd quartiles.
Table I. Median values and p-values from barrier measurements as well as ceramide/cholesterol ratio
Median values (percentiles 1 and 3) Significance using Friedman’s test Significance using Wilcoxon’s paired test
TEWL after treatment p = 0.027 No significance
Betamethasone 2.98 (2.43–4.25)
Emollient 3.67 (2.81–4.69)
Tacrolimus 3.18 (2.63–4.14)
Untreated control 3.40 (3.13–4.55)
TEWL after SLS p > 0.05 Not performed
Betamethasone 14.95 (11.60–21.53)
Emollient 18.20 (15.00–30.45)
Tacrolimus 18.25 (12.25–27.65)
Untreated control 15.45 (13.38–23.73)
Erythema after treatment p = 0.026 Significance between betamethasone vs. 
tacrolimus (p = 0.016) and betamethasone vs. 
untreated control (p = 0.004)
Betamethasone 7.86 (6.87–8.13)
Emollient 8.55 (7.18–8.70)
Tacrolimus 8.30 (7.58–8.62)
Untreated control 8.30 (7.47–13.33)
Erythema after SLS p = 0.044 Significance between emollient vs. 
betamethasone (p = 0.01) and emollient 
(p = 0.024) vs. untreated control and emollient 
vs. tacrolimus (p = 0.001)
Betamethasone 11.37 (9.85–13.08)
Emollient 12.49 (11.6–14.27)
Tacrolimus 11.54 (9.58–13.72)
Untreated control 11.57 (9.85–13.33)
Capacitance after treatment p > 0.05 Not performed
Betamethasone 33.50 (28.25–38.63)
Emollient 32.25 (29.50–34.86)
Tacrolimus 35.50 (32.13–39.63)
Untreated control 31.50 (27.75–34.86)
Ceramide/cholesterol ratio p = 0.050 Significance between emollient vs. 
betamethasone (p = 0.008) and emollient vs. 
tacrolimus (p = 0.025) 
Betamethasone 1.75 (1.25–2.03)
Emollient 1.20 (0.95–1.45)
Tacrolimus 1.40 (1.30–1.53)
Untreated control 1.50 (1.20–2.00)
TEWL: trans-epidermal water loss, in g/m2/h; SLS: sodium lauryl sulphate.
Erythema: colour from green to red measured by a cromometer (range: 0–60).
Capacitance: electrical resistance in the skin and expressed in arbitrary units that correlates to the water level in the stratum corneum (range: 0–120).
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fluenced mainly by the lipid and protein composition of 
the SC (3, 4). Very few studies have, however, focused 
on the SC lipids in relation to topical treatment regimes, 
and to the best knowledge of the authors, this is the first 
human study to describe the consequences of the use of 
topical corticosteroids on SC ceramides. One previous 
study has examined the SC lipids in a mouse model, as 
well as in vitro in human keratinocytes. In both models 
corticosteroid was applied topically, and a decrease in 
lamellar body generation and epidermal lipid synthesis 
in mice (n = 4) and in in vitro human keratinocytes (n = 5) 
were found (16). Another study examining the skin bar-
rier structure using transmission electron microscopy, 
found an inconsistency in the extracellular lipid bilayers 
after treatment with betamethasone in patients with AD 
(11). These findings suggested a negative barrier effect 
from topical corticosteroids. 
The actual effect of betamethasone and tacrolimus 
can be seen when comparison with the emollient-treated 
skin is made, since emollient-treated skin represents the 
changes from treatment without active ingredients, but 
with the effects from the emollient itself. The emol-
lient Olefin® was chosen for its simplicity; however, it 
should be noted that the present study does not examine 
whether other emollients would have the same effects 
on the skin barrier. 
By using volunteers with healthy skin, we ensured 
that the skin of each individual was homogeneous. 
Examining patients with AD or psoriasis, might make 
it impossible to use four areas on the forearms that were 
affected the same, and thereby make interpretation of 
the results more difficult. However, the results from the 
present study should be interpreted keeping in mind 
that patients with AD and psoriasis are known to have 
a low ceramide/cholesterol ratio, especially on lesional 
skin (5–8, 26). 
We found a statistically significant higher ceramide/
cholesterol ratio for betamethasone compared with 
emollient-treated skin, and a tendency towards a higher 
ceramide/cholesterol ratio for betamethasone compared 
with the untreated control area. For people with AD, an 
increased ceramide/cholesterol ratio is usually interpre-
ted as a barrier-positive increase, based on the decreased 
ceramide/cholesterol ratio found in AD skin (6). We 
found no difference in the subgroups of ceramides. 
With respect to values after SLS irritation, the TEWL 
values were found to be in agreement with the positive 
barrier hypotheses from the ceramide/cholesterol ratio, 
since the betamethasone-treated area presents the lowest 
TEWL (Table I). However, the reservoir effect on the 
skin from the topical drugs could result in vasoconstric-
tion and might also contribute to the reduction in TEWL 
and erythema values. 
Topical treatment with tacrolimus caused a signifi-
cantly higher ceramide/cholesterol ratio compared with 
emollient, suggesting an overall positive effect on the 
skin barrier function similar to that of betamethasone. 
For tacrolimus, only one human study on SC lipids has 
been published previously. It was speculated that topical 
treatment with tacrolimus might change the ceramide 
content of SC (13). Therefore, the ceramide profile for 
seven patients with AD was compared before the start 
and after 28 days of treatment with tacrolimus. The 
authors found a decrease in ceramide 4, but no compa-
risons with other topical treatment regimes were made 
(13). 
The present study analysed healthy individuals, and 
found no difference in ceramide subgroups after treat-
ment with tacrolimus, compared with betamethasone, 
emollient or untreated control. We were not able to 
confirm the formerly described decrease in ceramide 
4 described in seven patients with AD, who had an 
abnormal ceramide subgroup composition from the 
onset (13). 
For the water content of the SC, none of the treatment 
regimes changed the capacitance significantly compared 
with untreated skin. This result is in agreement with a 
study comparing five different moisturizers, of which 
they found no change in capacitance, but in contrast to 
longer-term studies suggesting that the use of a simple 
moisturizer can increase capacitance (14, 27). 
Our results indicate that the active ingredients in 
betamethasone and tacrolimus have a positive effect 
on ceramide/cholesterol ratio compared with treatment 
with emollient, as well as diminish the response to 
application of an irritant (SLS).
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